A
Andrea Marcellusi
Researcher at University of Rome Tor Vergata
Publications - 164
Citations - 1611
Andrea Marcellusi is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Medicine & Indirect costs. The author has an hindex of 19, co-authored 136 publications receiving 1248 citations. Previous affiliations of Andrea Marcellusi include Sapienza University of Rome & University of Genoa.
Papers
More filters
Journal ArticleDOI
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study
Gabriella Ferrandina,Giovanna Mantegna,Marco Petrillo,Gilda Fuoco,Laura Venditti,Serena Terzano,Cristina Moruzzi,Domenica Lorusso,Andrea Marcellusi,Giovanni Scambia +9 more
TL;DR: Lymphedema and menopausal symptoms were the most disabling treatment-related sequelae; the amount of QoL issues and their multifaceted aspects require the cooperation of multidisciplinary teams.
Journal ArticleDOI
The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases:
Corrado Blandizzi,Paolo Gionchetti,Alessandro Armuzzi,Roberto Caporali,Sergio Chimenti,Rolando Cimaz,Luca Cimino,Giovanni Lapadula,Paolo Lionetti,Antonio Marchesoni,Andrea Marcellusi,FS Mennini,Carlo Salvarani,Giampiero Girolomoni +13 more
TL;DR: Adalimumab, a fully human monoclonal antibody, has been approved for treatment ofnine distinct IMID indications and it is likely to become a valuable therapeutic tool for this complex cluster of chronic inflammatory disorders.
Journal ArticleDOI
Adalimumab in the treatment of immune-mediated diseases.
Giovanni Lapadula,Antonio Marchesoni,Alessandro Armuzzi,Corrado Blandizzi,Roberto Caporali,Sergio Chimenti,Rolando Cimaz,Luca Cimino,Paolo Gionchetti,Giampiero Girolomoni,Paolo Lionetti,Andrea Marcellusi,FS Mennini,Carlo Salvarani +13 more
TL;DR: Current clinical evidence shows adalimumab to be a valuable resource in the management of IMIDs, and analysis of indirect costs shows that ad alimumab significantly reduces social costs associated with RA, PsA, AS, Crohn's disease and psoriasis.
Journal ArticleDOI
Cost of poor adherence to anti-hypertensive therapy in five European countries
FS Mennini,FS Mennini,Andrea Marcellusi,Andrea Marcellusi,J.-M. Graf von der Schulenburg,Alastair Gray,Pierre Levy,Paolo Sciattella,M. Soro,Gianandrea Staffiero,Jan Zeidler,Aldo P. Maggioni,Roland E. Schmieder +12 more
TL;DR: In this article, a probabilistic prevalence-based decision tree model was developed to estimate the direct costs of cardiovascular disease related to hypertension in five European countries (Italy, Germany, France, Spain and England).
Journal ArticleDOI
Economic Burden of Human Papillomavirus-Related Diseases in Italy
Gianluca Baio,Alessandro Capone,Andrea Marcellusi,Francesco Saverio Mennini,Francesco Saverio Mennini,Giampiero Favato +5 more
TL;DR: The fraction of the total direct lifetime costs attributable to HPV 6, 11, 16, and 18 infections, and the economic burden of noncervical HPV-related diseases carried by men, were found to be cost drivers relevant to the making of informed decisions about future investments in programmes of HPV prevention.